Lupin receives US FDA approval for Novartis generic

NEW DELHI: The United States Food and Drug Administration (US FDA) has granted Indian drug maker Lupin final approval to market a generic version of Swiss pharmaceutical giant Novartis’ tobramycin inhalation solution ‘Tobi’.

The drug is used to treat cystic fibrosis patients with P. aeruginosa.

Tobramycin inhalation solution USP, 300 mg/5 ml, had sales of $133.6 million in the US as of December 2016, Lupin stated in a release about the development.

Share prices of Lupin rose 1.58 per cent to close at Rs1,490 on the Bombay Stock Exchange on Thursday, while the benchmark Sensex ended 0.56 per cent higher.